Connie M Rhee1,2, Kamyar Kalantar-Zadeh1,2, Katherine R Tuttle3,4,5. 1. Harold Simmons Center for Kidney Disease Research and Epidemiology, University of California Irvine School of Medicine, Orange, California. 2. Tibor Rubin Veterans Affairs Long Beach Healthcare System, Long Beach, California. 3. Providence Healthcare, Spokane. 4. Nephrology Division and Kidney Research Institute. 5. Institute of Translational Health Sciences, University of Washington, Seattle, Washington, USA.
Abstract
PURPOSE OF REVIEW: Diabetes mellitus is a leading cause of chronic kidney disease (CKD) that confers faster kidney disease progression, higher mortality, and various metabolic derangements including hypoglycemia. RECENT FINDINGS: Even in the absence of diabetes mellitus, growing research demonstrates that CKD patients are at heightened risk for hypoglycemia via multiple pathways. In CKD patients transitioning to end-stage renal disease (ESRD), spontaneous resolution of hyperglycemia and frequent hypoglycemia resulting in reduction and/or cessation of glucose-lowering medications are frequently observed in a phenomenon described as 'burnt-out diabetes'. In non-CKD patients, it is well established that hypoglycemia is causally associated with mortality, with pathways including arrhythmias, sudden cardiac death, stroke, and seizures. Increasing evidence shows that, in CKD and ESRD patients with and without diabetes mellitus, hypoglycemia is associated with cardiovascular complications and mortality risk. SUMMARY: Given the high prevalence of hypoglycemia in CKD patients and the morbidity and mortality associated with this metabolic complication, a multimodal strategy is needed to prevent dysglycemia, including individualization of glycemic targets, selection of glucose-lowering medications less likely to induce hypoglycemia, medical nutrition therapy administered by trained dietitians, and accurate and precise hypoglycemia detection methods, such as self-monitored blood glucose or continuous glucose monitoring including during dialysis treatment.
PURPOSE OF REVIEW: Diabetes mellitus is a leading cause of chronic kidney disease (CKD) that confers faster kidney disease progression, higher mortality, and various metabolic derangements including hypoglycemia. RECENT FINDINGS: Even in the absence of diabetes mellitus, growing research demonstrates that CKD patients are at heightened risk for hypoglycemia via multiple pathways. In CKD patients transitioning to end-stage renal disease (ESRD), spontaneous resolution of hyperglycemia and frequent hypoglycemia resulting in reduction and/or cessation of glucose-lowering medications are frequently observed in a phenomenon described as 'burnt-out diabetes'. In non-CKD patients, it is well established that hypoglycemia is causally associated with mortality, with pathways including arrhythmias, sudden cardiac death, stroke, and seizures. Increasing evidence shows that, in CKD and ESRD patients with and without diabetes mellitus, hypoglycemia is associated with cardiovascular complications and mortality risk. SUMMARY: Given the high prevalence of hypoglycemia in CKD patients and the morbidity and mortality associated with this metabolic complication, a multimodal strategy is needed to prevent dysglycemia, including individualization of glycemic targets, selection of glucose-lowering medications less likely to induce hypoglycemia, medical nutrition therapy administered by trained dietitians, and accurate and precise hypoglycemia detection methods, such as self-monitored blood glucose or continuous glucose monitoring including during dialysis treatment.
Authors: Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner Journal: Circulation Date: 2017-01-25 Impact factor: 29.690
Authors: Connie M Rhee; Csaba P Kovesdy; Vanessa A Ravel; Elani Streja; Steven M Brunelli; Melissa Soohoo; Keiichi Sumida; Miklos Z Molnar; Gregory A Brent; Danh V Nguyen; Kamyar Kalantar-Zadeh Journal: Diabetes Care Date: 2017-06-07 Impact factor: 19.112
Authors: Katherine R Tuttle; Mark C Lakshmanan; Brian Rayner; Robert S Busch; Alan G Zimmermann; D Bradley Woodward; Fady T Botros Journal: Lancet Diabetes Endocrinol Date: 2018-06-14 Impact factor: 32.069
Authors: Peter Novodvorsky; Alan Bernjak; Elaine Chow; Ahmed Iqbal; Lianne Sellors; Scott Williams; Robert A Fawdry; Bhavin Parekh; Richard M Jacques; Jefferson L B Marques; Paul J Sheridan; Simon R Heller Journal: Diabetes Care Date: 2017-02-17 Impact factor: 19.112
Authors: Alice P S Kong; Xilin Yang; Andrea Luk; Kitty K T Cheung; Ronald C W Ma; Wing Yee So; Chung Shun Ho; Michael H M Chan; Risa Ozaki; Chun Chung Chow; Nicola Brown; Juliana C N Chan Journal: BMC Endocr Disord Date: 2014-06-13 Impact factor: 2.763
Authors: Juan P Frías; Melanie J Davies; Julio Rosenstock; Federico C Pérez Manghi; Laura Fernández Landó; Brandon K Bergman; Bing Liu; Xuewei Cui; Katelyn Brown Journal: N Engl J Med Date: 2021-06-25 Impact factor: 91.245
Authors: Klara R Klein; Virginia Pate; Magdalene M Assimon; Til Stürmer; John B Buse; Jennifer E Flythe Journal: Diabetes Care Date: 2022-09-01 Impact factor: 17.152